Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a positive outlook with strong financial improvements, reduced net loss, and promising trial data for Symvess, which is expected to drive future growth. The Q&A section highlights positive feedback from hospitals and surgeons, successful cost-saving measures, and strategic expansion plans. Despite some unclear responses, the overall sentiment is optimistic, supported by strong data and strategic initiatives, likely leading to a positive stock price movement.
Key Financial Performance
Revenue for Q3 2025 $0.8 million, of which $0.7 million related to U.S. sales of Symvess. This is a significant increase compared to no revenue in Q3 2024. The increase is attributed to the commercial launch of Symvess and growing adoption by hospitals and healthcare systems.
Revenue for 9 months ended September 30, 2025 $1.6 million, of which $0.9 million related to U.S. sales of Symvess and $0.6 million from a research collaboration. There was no revenue for the same period in 2024. The increase is due to the commercial launch of Symvess and research collaborations.
Cost of Goods Sold (COGS) for Q3 2025 $0.3 million, compared to no COGS in Q3 2024. This includes overhead related to unused production capacity, reflecting the initial stages of commercial production.
Cost of Goods Sold (COGS) for 9 months ended September 30, 2025 $0.6 million, compared to no COGS in the same period in 2024. This reflects the costs associated with the commercial production of Symvess.
Research and Development (R&D) expenses for Q3 2025 $17.3 million, compared to $22.9 million in Q3 2024. The decrease is primarily due to the capitalization of material and overhead costs for commercial manufacturing and cost reductions implemented earlier in 2025.
Research and Development (R&D) expenses for 9 months ended September 30, 2025 $54.7 million, compared to $67.9 million in the same period in 2024. The decrease is due to reduced material costs, capitalization of inventory expenditures, and the winding down of certain clinical trial programs.
Selling, General, and Administrative (SG&A) expenses for Q3 2025 $7.6 million, compared to $7.3 million in Q3 2024. The increase is attributed to the U.S. commercial launch of Symvess, including increased personnel expenses.
Selling, General, and Administrative (SG&A) expenses for 9 months ended September 30, 2025 $23.6 million, compared to $18.4 million in the same period in 2024. The increase is due to expenses related to the commercial launch of Symvess.
Other Net Income for Q3 2025 $6.9 million, compared to a net expense of $9.0 million in Q3 2024. The increase is primarily due to the noncash remeasurement of the contingent earn-out liability from the 2021 merger.
Other Net Income for 9 months ended September 30, 2025 $61.3 million, compared to a net expense of $41.5 million in the same period in 2024. The increase is due to the noncash remeasurement of the contingent earn-out liability.
Net Loss for Q3 2025 $17.5 million, compared to $39.2 million in Q3 2024. The decrease is due to the noncash remeasurement of the contingent earn-out liability, reduced operating expenses, and a decrease in loss from operations.
Net Loss for 9 months ended September 30, 2025 $16.0 million, compared to $127.8 million in the same period in 2024. The decrease is attributed to the same factors as the quarterly reduction in net loss.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Symvess commercial launch: Traction gained with surgeons and hospitals; 92 civilian hospitals approved for purchase; $703,000 in product sales this quarter, up from $100,000 last quarter.
Symvess in military facilities: First commercial sale to U.S. military facilities after ECAT approval; interest in improving medical options for military personnel.
Symvess publications: Three studies published demonstrating effectiveness in vascular trauma, including hospital-acquired complications, wartime injuries in Ukraine, and comparison to autologous vein.
ATEV for dialysis access: Positive 2-year results from V007 Phase III trial; superior duration of use over 24 months compared to autogenous fistula; targeting underserved populations like women and high-risk men.
CTEV for coronary artery bypass grafting: Positive preclinical results; IND filed with FDA; first-in-human study planned for 2026.
Expansion into military healthcare: Symvess now available to military treatment facilities and U.S. Department of Veterans Affairs Hospitals.
Revenue growth: $0.8 million revenue this quarter, $0.7 million from Symvess sales, up from $0.1 million last quarter.
Cost management: Decreased R&D expenses due to capitalization of manufacturing costs and winding down of clinical trials.
Intellectual property expansion: New U.S. patent granted for bioengineered esophagus, providing protection until 2041.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Adoption Challenges: Despite progress in VAC approvals and increased product sales, the company faces challenges in achieving widespread adoption of Symvess, as evidenced by the ongoing review processes in 45 additional hospitals or health systems.
Regulatory and Approval Risks: The company’s plans to expand indications for its products, such as the ATEV for dialysis access, are contingent on successful interim analysis and regulatory approvals, which carry inherent risks of delays or non-approval.
Supply Chain and Production Costs: The cost of goods sold includes overhead related to unused production capacity, indicating potential inefficiencies or underutilization in manufacturing operations.
Financial Sustainability: The company reported a net loss of $17.5 million for Q3 2025 and $16.0 million for the first nine months of 2025, raising concerns about its ability to achieve profitability in the near term.
Competitive Pressures: Symvess faces competition from the current standard of care, autologous vein, which has established efficacy and safety profiles, potentially limiting market penetration.
Economic and Funding Risks: The company’s cash position, even after a recent stock and warrant sale, provides a runway of just over 12 months, highlighting the need for additional funding to sustain operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercial Expansion of Symvess: The company is actively engaging with surgeons and clinicians, observing increased hospital orders and reorders for Symvess. Symvess has been approved for purchase by 92 civilian hospitals, with 45 additional hospitals currently reviewing the product. The company anticipates further adoption and validation of Symvess through ongoing research and publications.
U.S. Defense Logistics Agency ECAT Approval: Symvess has been approved for the Electronic Catalog (ECAT) listing, making it available to healthcare professionals treating military personnel and veterans. The company has recorded its first commercial sale to U.S. military facilities and is advancing discussions with additional DoD-affiliated hospitals.
Dialysis Access Program: Positive 2-year results from the V007 Phase III trial of ATEV in dialysis patients were presented, showing superior duration of use over 24 months compared to autogenous fistula. Interim analysis results from the ongoing V012 Phase III trial are expected by April 2026, with plans to submit a supplemental BLA in the second half of 2026 to add dialysis access as an indication for ATEV.
Coronary Tissue Engineered Vessel (CTEV) Program: The company plans to advance the CTEV into a first-in-human study for coronary artery bypass grafting (CABG) in 2026. An IND has been filed with the FDA for this indication.
Intellectual Property Expansion: A new U.S. patent has been granted for the composition of a bioengineered esophagus, providing protection until 2041. This expands the company's tubular prosthesis patent family, which includes engineered trachea, urinary conduits, and esophagus.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How many hospitals that started ordering have begun the reorder process?
A:The company has not disclosed specific data, but the majority of hospitals that started ordering have reordered.
Q:How does the new data from the trial for 007 change the view for the potential for Symvess in dialysis?
A:The strong results in duration of usability in high-need subgroups going out to 2 years are significant. This data supports the eventual filing of a supplemental BLA application in dialysis access, as these subgroups represent more than half of the dialysis population.
Q:Out of the units purchased, how many have been used versus initial stocking orders?
A:Initial stocking orders range from 1 to 3 units. Hospitals typically reorder when they fall below their par level. Feedback from surgeons has been positive regarding the product's ease of use and functionality.
Q:What benefits have been seen from the price reduction of Symvess?
A:The price reduction has accelerated the VAC process and reopened doors with hospitals that previously did not consider the product. Hospitals are moving through the VAC process quicker, and there has been an acceleration in both VAC submissions and time for approval.
Q:Are the cost savings initiatives for '25 and '26 on track?
A:Yes, the company is on track to achieve $50 million in cost savings. Operating expenses have already been reduced by about $5 million quarter-over-quarter.
Q:How impactful has the supportive evidence for Symvess in vascular trauma been?
A:The steady publications and long-term outcomes have been powerful in bringing surgeons on board. A post-approval registry study for 100 trauma patients is planned to start in the first half of 2026, with initial data expected 6-12 months after.
Q:Will the interim analysis for the first 80 patients in V012 be robust enough for FDA approval?
A:Yes, if the interim analysis shows superiority of the vessel compared to the gold standard fistula in dialysis, it would be supported by data from V007, providing two prospective randomized studies for FDA consideration.
Q:How will the sales force transition to support the commercial opportunity for dialysis?
A:The current sales force of 12 agents will be strategically expanded. By 2027, an additional 10-20 representatives may be added to target the same surgeons but in outpatient facilities for dialysis access.
Q:What is the status of programs for esophagus, trachea, and urinary conduit replacements?
A:These programs are not actively advancing due to prioritization of resources. The company plans to revisit these as revenues increase and cash position improves.
Q:What is the plan regarding the NTAP submission?
A:The company has decided not to resubmit for NTAP in trauma due to CMS's decision and has instead focused on price reductions to drive market activity.
Q:Have there been additional hospital orders and expansion beyond initial implanting physicians?
A:Yes, some hospitals have seen usage beyond the initial champion surgeon. However, individual contracting is still required for hospitals within approved systems.
Q:How does the company initiate and maintain conversations on value proposals with VAC committees?
A:The company uses a Budget Impact Model showing cost savings from reduced complications. The new price point has strengthened this argument, though some hospitals still focus on initial acquisition costs.
Q:What are the current cash use expectations and runway?
A:Cash on hand is expected to last beyond 12 months, covering milestones like interim results from V012, BLA filing for dialysis, and commencement of human testing in cardiac bypass graft surgery.
Q:Review of Unclear Management Responses
A:Management avoided directly answering how many hospitals that started ordering have begun the reorder process, stating only that the majority have reordered without providing specific data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CTEV
Complications
ECAT approval
II III
III study
III trial
Journal
PROOVIT registry
Phase II
Phase III
Symvess outcome
Symvess research
Symvess vein
Ukraine
Vascular
alternative
blood flow
combat
complication
conduit
death
decrease research
duration
engagement
esophagus
expense period
health care
income month
infection rate
injury vein
launch Symvess
loss month
loss period
month period
outcome patient
patent
patient injury
period decrease
procedure
publication
rate fistula
result study
HUMA Transcript
Humacyte, Inc. (HUMA) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary lacks substantial information on key areas such as financial performance, strategic initiatives, and risks. The absence of details and unclear management responses in the Q&A suggest a lack of transparency. Without positive or negative catalysts, the stock price is unlikely to experience significant movement, leading to a neutral prediction.
Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript
Unknown3-27
The earnings call lacks critical financial details, such as revenue, margins, and cash flow figures, creating uncertainty. The absence of discussions on operational updates and shareholder returns further adds to the negative sentiment. Forward-looking statements are heavily caveated with risks, and there is no positive guidance or strategic plan provided. These factors suggest a negative market reaction.
Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-6
HUMA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
